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Baseline BMI, Gender, & Age as Predictive Factors for Intragastric Balloon Weight Loss Outcomes
Miranda Myers-Burton, PA-S & Nirali Shah, PA-S
James Madison University

ABSTRACT
Objective: To determine whether obese and morbidly obese patients aged 18-75 with a lower baseline
BMI (BMI 30-39.9 kg/m2) who received an intragastric balloon (IGB), have a higher percentage of total
body weight loss (%TBWL) and percentage of excess weight loss (%EWL) compared to those with a
higher baseline BMI (BMI > 40 kg/m2). Secondary objective was to ascertain whether gender and age are
also predictors of weight loss outcomes following an IGB procedure.
Design: Systematic literature review
Methods: Literature searches of PubMed and SpringerLink were conducted using the search terms:
“intragastric balloon, weight loss, and “BMI” and then limited to publications within the years 2010-2020.
The following limits were used: study available in the English language, patients 18 years or older, results
stratification by BMI, and study designs that were randomized control trials, cohorts, or case controls
followed for six months total.
Results: Using the keywords mentioned above in PubMed and SpringerLink, three studies met the
inclusion and exclusion criteria: a prospective cohort study by Diab et al., a case control study by LopezNava et al., and a prospective cohort study Lecumberri, et al.
Conclusion: No significant difference in %TBWL was found in all the studies reviewed. All three studies
concluded that gender had little difference in weight loss outcomes, however there was variability in
conclusions on age and baseline BMI. Two out of three studies ascertained that younger patients and
patients with lower baseline BMI show greater %EWL, concluding that baseline BMI and age can be used
as predictors of IGB weight loss outcomes.

INTRODUCTION
Since the 1970s, obesity has become a serious health epidemic affecting Americans of all races,
gender, and ages.1 Obesity is the result of complex associations of genetics, diet, socioeconomic status,
culture, medical and pharmacological factors.1,2 Data from the Behavioral Risk Factor Surveillance
System Survey (BRFSS) collected between 1990 through 2016 predict that by 2030, there will be an
estimated 33% increase in obesity, and 130% increase in severe (morbid) obesity. This means that in ten
years, at least 1 in 2 Americans adults will be obese, and nearly 1 in 4 morbidly obese.3,4
According to the Center for Disease Control and Prevention (CDC), obesity is defined as a Body
mass index (BMI) of 30.0 or higher.5 Morbid obesity, also known as severe, extreme, or class 3 obesity, is
defined as a BMI of 40.0 or greater.5 In the last five decades, the alarming increase in obesity rates in the
United States (U.S.) can be attributed to unhealthy diets and increased sedentary lifestyles. 1,2,6 Of the top
ten leading causes of death in the U.S., risk factors for seven of them include obesity, including heart
disease and cancer which rank as the top two on the list.7 Additionally, chronic lower respiratory diseases,
cerebrovascular accidents, Alzheimer’s, diabetes, and kidney disease also have obesity as a risk factor7
Other major health conditions associated with obesity include sleep apnea, hepatobiliary disease,
osteoarthritis, gynecological and psychiatric disorders.1,2 Individuals with obesity are at a much higher risk
of mortality related to associated complications of these diseases. 1.2
Obesity is currently managed with a combination of approaches that include lifestyle and dietary
changes, pharmaceutical therapy, and in more severe cases bariatric procedures. Out of the various
management strategies, Roux-en-Y gastric bypass (RYGP), and various other bariatric surgeries are

considered the most successful long-term interventions for weight loss compared to intensive behavioral
modification or pharmaceutical therapy either combined or alone. 8,9 However, all bariatric surgeries come
with significant complications and limitations that bar the majority of obese patients from receiving them.
For example, gastric bypass recipients are at risk for long-term vomiting and diarrhea, gastric ulcers,
strictures, small bowel obstructions, hernias, dumping syndrome and malnutrition in addition to typical
surgical risks of infection, blood clots, and internal bleeding.10 In recent years, alternatives to gastric
bypass surgery for severe obesity treatment, such as endoscopic intragastric balloon systems, have been
explored.
Intragastric balloon (IGB) systems were first approved in the US for the treatment of obesity in
11
1985. Since then, there have been many different IGB systems developed to be utilized as an effective,
minimally invasive method of weight loss in obese individuals. These balloon systems lead to weight loss
by inducing early satiety, ultimately leading to decreased food intake.11 IGBs used today are made of
silicone, polyurethane, nylon, titanium, gelatin or polymer films which can be swallowed, or more
commonly, endoscopically placed.11,12 These balloons are then filled with 250-900 milliliters of nitrogen,
air, or saline.11,12 The total number of balloons placed can range from 1-3 and can remain intragastric for
up to 12 months. The balloons can be removed endoscopically, or excreted naturally. 11,12 The
complications associated with IGB range from mild, self-limiting complications such as pain, nausea and
vomiting to more serious complications such as intestinal obstruction, perforations, and bleeding. 13 A
meta-analysis on the safety and effectiveness of IGBs of more than 3,000 patients found that only 4.2%
experienced complications significant enough to warrant early removal of the balloons. 14 The hope with
the intragastric balloon is to reach obese patients ineligible for bariatric surgery with a less invasive,
reversible, and affordable option that can be used as an adjunct to other weight loss methods.
Several studies on gastric bypass surgery have ascertained that patients with lower baseline BMI
see more weight loss success following the procedure than those with higher baseline BMI.15,16,17,18,19
However, the presence of predictive factors such as baseline BMI, gender, and age have not yet been
systematically reviewed and established for intragastric balloons. Defining predictors of weight loss
success will help guide the selection of patients best eligible for the intragastric balloon, and in turn save
on healthcare costs and reduce patient complications. 18,19 The goal of this systematic review is to
ascertain whether the limiting factor of higher baseline BMI as a predictor for gastric surgery weight loss
outcomes, is similarly associated with the less invasive intragastric balloon procedure.

METHODS
Literature searches of both PubMed and SpringerLink were conducted in September 2020 using
the search terms: “intragastric balloon, weight loss, and “BMI” limited to publication within the years 20102020. The following other limits were used: study available in the English language, patient sample only
including those 18 years or older, stratification of results by BMI, and only randomized control trials,
cohorts, or case controls which followed the study group for six months. Studies that were case reports,
meta-analyses, and literature reviews were excluded, as well as studies that were noted to have
confounding variables, did not compare the desired variables, had significantly small sample sizes, or had
significant loss to follow-up. Based on these inclusion and exclusion criteria, three articles comparing
baseline BMI and weight loss outcomes following an intragastric balloon procedure were identified and
included in this literature review. This process is outlined in the form of a PRISMA flowchart in Figure 1.

RESULTS
Study 1: The Effect of Age, Gender, and Baseline BMI on Weight Loss Outcomes in Obese Patients
Undergoing Intragastric Balloon Therapy.20
Study Objective
To evaluate age and gender and baseline BMI as predictors of weight loss in obese patients
treated with intragastric balloons.
Study Design
This was a prospective cohort study that enrolled and followed 229 patients receiving an Orbera
intragastric balloon procedure between June 2014 and December 2017 at the Khaldi Medical Center in
Amman, Jordan.
After obtaining informed consent, the patients were sedated with propofol for endoscopic balloon
placement. Esophagogastroduodenoscopy was performed followed by placement of the Orbera
intragastric balloon down the esophagus into the stomach. The balloons were filled with 600-650 ml of
normal saline and 10 ml of methylene blue. Placement of the balloons within the stomach were confirmed
with endoscope visualization during the procedure. For the six-month period, patients were placed on a
thousand calorie diet and followed by a multidisciplinary team.
Six months following the procedure at the time of balloon removal, data was collected on percent
excess weight loss (%EWL), total body weight loss (TBWL), and percent total body weight loss (%TBWL).
The data was stratified into categories based on gender, age groups, and baseline BMI. Patients were
categorized according to two age groups: age less than 40 years and age ≥ 50 years. Patients who were
40-49 years of age were later excluded from the study. The patients were also studied in two baseline
BMI groups: BMI < 35 and BMI > 40. No patients with the BMI of 35-40 were ultimately included in the
study. Following these exclusions, 184 patients, 80% of which being female and 73% younger than 40
years old, were ultimately enrolled in this study.
Primary outcomes measured were the effect of age, gender, and baseline BMI on weight loss and
means of TBWL, %EWL, and %TBWL amongst the stratified groups.
Table 1. Study #1 Patient Criteria
Inclusion Criteria
1. Age less than or equal to 30 and greater
than or equal to 50
2. Baseline BMI less than or equal to 35 and
greater than or equal to 40
3. Patients who had not received weight loss
therapy for at least 8 months before
placement of the intragastric balloon
4. Patients who completed the full 6 months
period of balloon placement with
successful balloon removal
Study Results

Exclusion Criteria
1.
2.
3.
4.
5.
6.
7.
8.

Age 40-49
Baseline BMI 35-40
Previous esophageal or gastric surgery
More than 2 cm hiatal hernia
Active gastric ulcers
Coagulopathy
Early balloon removal
Spontaneous balloon deflation

The study found that %TBWL was not found to be significantly different between age groups or
genders, however TBWL was higher amongst males compared to females. The study also concluded that
higher baseline BMI had higher TBWL compared to lower baseline BMI in both sexes. Additionally, there
was a significant effect of age on weight loss in females, with percent excess weight loss of 47.34% in
females under age 40 and 38% in those over age 50. As displayed in Table 2, no significant difference
(“N.S.”) in %EWL was found between age groups in the male patients (50.21% in younger males and
47.05% in older males, p value=0.836).
Table 2. Study #1 Outcome after 6 months of intragastric balloon therapy based on age.

Lower baseline BMI was found to have a significant impact on %EWL compared to higher
baseline BMI in both genders: 53.7% for females with lower baseline BMI compared to 32.5% for females
with higher baseline BMI; and 50.1% for males with lower baseline BMI compared to 32.2% for males
with higher baseline BMI (p value <0.01) (see Table 3). Neither TBWL or %TBWL were significantly
different between baseline BMI groups among either gender group. However, when results from both
males and females were combined, higher baseline BMI had statistically significant higher TBWL
compared to the lower baseline BMI group.
Table 3. Study #1 Outcome after 6 months of intragastric balloon therapy based on baseline BMI.

The study also performed a Durbin Watson test, which analyzes serial correlations between
variables and assigns a value of 0-4 where 2 means no correlation. The study found there were no
residual correlations between age, gender, or baseline BMI amongst four age and sex subgroups (see
Table 4).

Table 4. Study #1 Outcomes for age, gender, baseline BMI subgroups.

Study Critique
One of this study’s strengths is strict inclusion criteria of those physical constraints that would
diminish the patient’s tolerance of the balloon such as active gastric ulcers. As a result of these criteria,
large loss to follow-up risk was reduced and an adequate sample size was maintained. Another strength
is strict adherence to post-procedure protocol for dietary restrictions and follow-up visits with a
multidisciplinary team, to reduce influence on weight loss outcomes from extraneous variables outside of
intragastric balloon placement.
There were many limitations to this study. The study excludes ages 40-49 and BMI 35-40 without
explanation as to why. Given that these exclusions were made, the conclusions of their study cannot be
extrapolated to patients of intermediate age or BMI. There is a possibility that the results of the study and
their statistical significance may have been different if the participants of the study within those age and
BMI ranges had not been excluded following recruitment. Additionally, the study has a small sample size
for males. The researchers admit that they could not be confident that the lack of significant effect of age
in males is not just because of a type 2 error. The researchers also pointed out that they did not take into
account comorbidities such as hypertension, hyperlipidemia, or diabetes mellitus which could have
influenced the weight loss outcomes of the study participants. Lastly, the study did not include patients
that received the balloon and had it removed before the 6 month expected period, meaning the study
provided results using per protocol analysis, rather than intention-to-treat analysis and thus did not
compare the approaches nor prove their equivalence. By not calculating results with and without those
that dropped-out due to early balloon removal, it leaves the question whether the results with exclusions
were significantly different compared to results if all participants had been included.

Study 2: Dual Intragastric Balloon: Single Ambulatory Center Spanish Experience with 60 Patients in
Endoscopic Weight Loss Management.21
Study Objective
To study the safety and efficacy of the Dual Intragastric Balloon (DIGB) and to see how factors
such as the degree of obesity, age and gender of participants affected their response to treatment.
Study Design
This was a case control study following 60 participants, 49 women and 11 men, at a bariatric
endoscopy unit at the Madrid Sanchinarro University Hospital in Spain. The participants were patients
who were admitted to the unit between September of 2012 and June of 2013 and chosen based on the
inclusion and exclusion criteria listed in Table 5.
After sedation, gastric pathologies were first excluded using standard diagnostic endoscopy.
Next, with the participants in the left lateral decubitus position, a guide wire was positioned through the

endoscope into the stomach and advanced through the pylorus. A balloon delivery catheter was then
advanced and the DIGB was positioned at the greater curvature of the stomach. The DIGB consisted of
two independent silicone balloons which were bonded to a flexible silicone shaft which was attached to
the delivery catheter. Following delivery of the balloons into the stomach, under endoscopic visualization,
they were each filled with 450 cc of sterile saline/methylene blue solution using an automated pump..
Mean implantation time was 12 minutes, and mean duration of treatment was 6.9 months. .
Participants followed a specific diet consisting of a liquid diet 1 day prior to procedure and
continued until one-week post-placement of the balloons. Small semi-solid meals were progressively
started over the second week, hypo-caloric meals starting in the second week and continued until month
6-7. Individual preferences and energy requirements were taken into consideration. Participants were
also to follow-up with nutritionists and psychologists weekly or bi-weekly, as well as emphasizing initiating
an exercise program with progressive increase in intensity.
For assessing the participant’s progress, their height and weight were measured using calibrated
scales and wall mounted stadiometers without shoes, and indoor clothing kept on. Outcomes measured
included change in body weight (TBWL), percentage loss of initial body weight (%TBWL), and percentage
of excess weight loss (%EWL) which was the current weight minus the weight corresponding to BMI 25
kg/m2.
Statistical analysis methods included using the test of proportion for qualitative variables,
measurements of central tendencies (mean), and dispersion (standard deviation) for quantitative
variables. Student’s t-test for related pairs was used for statistical analysis of association of changes
comparing initial and final values of weight parameters. SPSS 17.p was used for data analysis with the
statistical significance set at a two tailed probability level of </= 0.05.
Table 5. Study #2 Patient Criteria.
Inclusion Criteria

Exclusion Criteria

-both male & female
-clinically obese (BMI above 30)
-willing & able to follow strict dietary and exercise
guidelines post-procedure
-willing & able to attend follow-up with a
multidisciplinary team post-procedure

- had an absolute contraindication to anesthesia

Study Results
Among morbidly obese and non-morbidly obese participants, morbidly obese patients had a
greater TBWL than non-morbidly obese participants: 20.52 + 10.39, and 14.49 + 8.07, respectively. There
was no significant difference found with TBWL regarding age or gender and no statistically significant
difference in %TBWL with regard to gender, age, or obesity grade. Women participants had a higher
%EWL compared to men: 50.73 + 26.68 for women, and 30.92 + 21.03 for men. This can be attributed to
the lower number of males in the study, as well as the fact that the women had a higher excess weight at
baseline compared to the male participants. Non-morbidly obese participants also had a higher %EWL
than morbidly obese participants, 52.27 + 28.72 and 37.48 + 19.72, respectively.
Regarding safety, there were no incidences of migration in the 6month life of the balloon. There
was one incidence of early removal due to patient intolerance, one early deflation, but without migration,
and finally one gastric perforation. 14 patients also had gastric ulcers or erosions at the time of removal,
however these were clinically insignificant.

Table 6. Study #2 results of TBWL, %TBWL and %EWL based on obesity grades, gender, and age >40
years or </=40 years.

Study Critique
The study had several strengths. The researchers discuss that the use of regular counseling and
multidisciplinary teams increase patient commitment to weight loss and long-lasting results. They endorse
the use of the psychological, nutritional, and physical activity support teams that had extensive
experience with the use of IGBs for treatment of obesity. Frequent visits with professionals yield
increased follow-ups, better monitoring and therefore better outcomes. This multidisciplinary approach
could be an important factor in higher %EWL. The authors also describe that the design with a dual
balloon decreases the risk of migration and therefore decreases the risk of perforations and other adverse
effects. The study also investigated a lower cost and more accessible alternative to bariatric surgery
which has the potential to fill a significant gap in treatment for a major public health crisis. Finally, this
study was one of the first to compare intragastric balloon weight loss outcomes amongst genders, ages,
and degrees of obesity.
The study also had a few weak points. Women had a higher %EWL but this could be attributed to
less male participants or higher excess weight at baseline for males. This limitation makes it difficult to
extrapolate results and apply them to both male and female obese and morbidly obese patients.
Additionally, the study did not specify inclusion and exclusion criteria when recruiting their participants,
therefore some inferences needed to be made. Not including this information explicitly, especially
regarding patient age and BMI ranges, makes it difficult to extrapolate to other patient populations,
compare results amongst studies, and to reproduce this study in the future. The researchers did not
disclose possible limitations of their study, did not discuss the possibility of confounding variables nor
specify in what ways they controlled for such possibilities.

Study 3: Effectiveness and Safety of Air-Filled Balloon Heliosphere BAG® in 82 Consecutive Obese
Patients.22

Study Objective
To describe the effectiveness, in regards to absolute weight loss, BMI loss, percentage of body
weight loss (%BWL), and percentage excess weight loss (%EWL), and complications 6 months postinsertion of the air-filled balloon in obese patients.
Study Design
Prospective study involving 84 patients from an outpatient endocrinology clinic following insertion
of an endoscopically placed air-filled intragastric balloon. Sixty-three of the participants were women, with
a mean age of 39 years and mean BMI of 39.1 kg/m2 among all participants.
Prior to insertion, anthropometrics were measured. The measurements were also repeated after
balloon removal. Height and weight were also measured in light clothing, without shoes, on a wall
mounted stadiometer. Balloons were inserted via endoscopic control following general anesthesia with
propofol 2mg/kg IV. After insertion, the balloons were inflated with 960cc of air to a final inflation volume
of 700cc. Following the procedure, patients fasted for 6-8 hours and were prescribed a high-protein liquid
diet for the first 24-72 hours. A soft low calorie to normal diet was initiated thereafter with a goal of 8001200 kcal/day. For any persistent nausea and vomiting for the first few days following insertion, patients
were prescribed Cisapride 10 mg BID or TID. Proton pump inhibitors were also prescribed for the duration
of balloon treatment. Patients were also advised to avoid alcohol, coffee, cola, and gastric secretion
stimulants and had planned monthly dietitian visits. Balloons were planned for endoscopic removal 6
months after insertion. Median time of removal was 182 days ranging from 63 days to 238 days.
Table 7. Study #3 Patient Criteria.
Inclusion Criteria
-

Overweight and obese patients (BMI > 27)
following insertion of air-filled intragastric
balloon

Exclusion Criteria
-

Serious psychiatric disorders
Drug abuse
Age <18 years, or >70 years
Previous gastrointestinal surgery
Active peptic ulcer
Big hiatal hernia
Severe gastritis or esophagitis
Coagulation disorders
Anti-inflammatory agents
Glucocorticoid therapy
Neoplasia
Potential for decompensation of renal or
heart disease

Study Results
Statistical analysis included paired t-test and McNemar test to compare baseline and outcome
variables; Linear regression analysis was used to evaluate for the associations of age, gender, initial BMI
with weight loss, BMI loss, percentage of initial body weight loss, and % EWL. Interaction and confusion
were also evaluated. Due to an outlier patient, analysis was done after excluding this data and results
were reported if differences were found to be significant (bilateral ɑ <0.05). SPSS 15.0 software was used
for computer analysis.
Only one early surgical removal was required due to technical problems with endoscopic
extraction, and there were two spontaneous deflations without migrations. One patient gained 6.4kg after
balloon placement due to a psychiatric disorder suspected after balloon placement. With the exception of

that case, weight loss ranged from 0.5kg to 43.5kg with a mean of 14.5kg (SD, 8.2; 95% Confidence
Interval (CI) for difference 12.7−16.4; p < 0.001). BMI loss ranged from 0.2-13.4kg/㎡, with an average
loss of 5.3kg/㎡ (SD 2.8; 95% CI for difference 4.7−5.9; p < 0.001). See Figure 1 and table 8 below for a
summary of the BMI changes before and after balloon removal. With adjustments for age and sex,
analysis of the results showed that the higher the baseline BMI, the greater the absolute weight loss and
BMI loss. However, a higher baseline BMI was found to have a lower percentage of EWL. The
percentage of BWL was not associated with the BMI at baseline, prior to balloon insertion. Age was found
to be inversely related to weight loss with multivariate regression analysis. There was also an association
found between age and BMI loss, %BWL, and %EWL, but only after exclusion of an outlier patient.
Mean %BWL loss was 13.4% (SD 7.0) and a mean %EWL was 33.2% (SD 19.20). Table 8
below summarizes the absolute weight loss, BMI loss, %BWL, and %EWL categorized by sex and initial
BMI.
Secondary findings also include that the longer the balloon was in place, the greater the absolute
changes in most outcomes measured compared to those removed earlier, around the six-month mark.
Thirty-nine patients who had the balloon in place for longer than six months compared to patients with
removal at six months had an average absolute weight loss of 17.25kg vs 12.42kg (p=0.013), average
BMI loss was 6.23 kg/㎡ vs 4.56kg/㎡ (p=0.012), average %BWL was 15.43% vs 11.85% (p=0.024).
There was no statistical difference in the average %EWL comparing removal time groups (35.08% vs
31.87% (p=0.459)), nor between men and women regarding weight loss, BMI loss, percentage of BWL,
and percentage of EWL.
Figure 1. Study # 3 BMI distribution by sex (a) before balloon insertion and (b) after balloon removal.

Table 8. Study #3 Weight loss, BMI loss, percentage of BW, and percentage of EWL according to sex
and initial BMI.

A portion of this study’s data included overweight participants with a BMI of 27.1-29.9 with
significant comorbidities (poorly controlled diabetes, hypertension, dyslipidemia, obstructive sleep apnea,
etc.) that they believed would benefit from the IGB. This portion of the data does not fit the inclusion
criteria of this literature review. Results excluding this data have been calculated by the writers of this
paper and provided in parentheses in Table 10 within the discussion section.
Study Critique
Some strengths of this study included its exclusion criteria as they were reasonable in order to
safely use individuals from the target population and to avoid any serious adverse effects for the patients,
as well as to avoid any factors that could alter the results of the IGB treatment. Another strength of this
study was the involvement of pharmacological therapy and dietitians to maximize the safety, tolerability
and benefits of the IGB treatment. Patients were prescribed PPIs for the treatment period and scheduled
to follow up monthly with the dietitians.
Some of the weaknesses include a disproportionately small number of male study participants.
This makes it difficult to extrapolate results regarding obese and morbidly obese male patients. The study
defined obesity as BMI > 27, which is not the most accepted definition per the American Medical
Association or the World Health Organization; this makes comparing and extrapolating results somewhat
difficult. Additionally, in the results section the researchers describe that one of the participants was
excluded from data analysis because a psychiatric disorder was suspected after balloon insertion. This
was also the only patient that gained weight during the study. Although the authors state that “results
were reported if differences were found”, it is not clear how many individuals were excluded and how
many used in their research. In the results section, the authors only describe two different patients
excluded from a previous total of 84, but for different reasoning: loss of measuring initial BMI in one
individual and final weight loss in another. The lack of clarity regarding exclusion of participants
undermines the validity of the analysis and results of the study.
DISCUSSION
The obesity epidemic in America is continuing to affect millions of Americans and is a major risk
factor for many of the top preventable causes of death. Several studies regarding gastric bypass have
ascertained that patients with lower baseline BMI see more weight loss success following the procedure

than those with higher baseline BMI.15,16,17,18,19 Many obese and morbidly patients fail nutritional and
pharmaceutical therapy, and may not be candidates for gastric bypass. Lopez-Nava etl al. describe that
although bariatric surgery result in significant weight loss in obese patients, <1% of the population
worldwide is eligible and able to receive the treatment. Intragastric balloon systems are a promising,
minimally invasive strategy to significantly reduce BMI in obese patients. This would safely allow them to
reach the parameters to ultimately receive bariatric surgery and therefore sustained weight loss and
improvement of comorbid conditions. In addition to exploring the differences in weight loss in relation to
baseline BMI, the studies included also reviewed other demographics such as age,gender, and the
correlation of weight loss success with the use of intragastric balloons. Table 9 and 10 summarize the
characteristics and findings of the systematically reviewed studies.
Table 9. Overview of Study Characteristics
Study #1: Diab et al.

Study #2: Lopez-Nava
et al.

Study #3: Lecumberri
et al.

Study type

Prospective Cohort

Case Control

Prospective Cohort

Sample Size

184

60

84

Population

Aged ≤ 30 years old

Aged 18 or older with

and ≥ 50 years old with

BMI ≥ 30 kg/㎡

Aged 18-70
Overweight with
significant comorbidity
and obese patients.

baseline BMI ≤ 35 kg/㎡
and ≥ 40 kg/㎡
Location

Al Khalidi Medical
Center in Amman,
Jordan

Madrid Bariatric
Endoscopic Unit of the
Sanchinarro University
Hospital in Madrid,
Spain

Endocrinology and
nutrition department of
San Carlos University
Hospital and
endocrinology
department of Santa
Elena Clinic in Madrid,
Spain

Balloon Type

Orbera; 600-650 cc
saline and 10cc
methylene blue solution

Dual Intragastric
Balloon; each filled with
450cc saline/methylene
blue solution

700cc Air filled
Heliosphere bag

Loss to Follow-Up

-

-

2 patients were
excluded due to weight
or height data missing.
1 patient was found to
have a psychiatric
disorder affecting their
weight and was
removed from the
study.

Complications

-

1 early removal due to
patient intolerance. 1
early deflation without

1 surgical removed due
to technical problems
with endoscopic

migration or surgical
removal.
1 gastric perforation.
14 gastric ulcers or
erosions at time of
removal, however
clinically insignificant.

extraction.
2 spontaneous
deflations without
migrations.

The primary endpoint of these studies was to determine safety and efficacy of the IGB.
Secondary endpoints included analyzing for a difference in percentage of excessive weight loss and
percentage of total body weight loss amongst two baseline BMI groups, and %EWL and %TBWL
differences amongst gender and age. The results stratified into subgroups is provided below in Table 10.
Table 10. Overview of Study Results
Study #1: Diab et al.

Study #2: Lopez-Nava et al.

%EWL

%TBWL

Male,
BMI <40

50.1±12.3

11.8±2.8

All
41.7±
participant 26.72
s

15.4±7.95 All
33.2
participant (32.4)
s

13.4
(12.8)

Male,

32.1±17.1

12.9±7.2

BMI <40,
Total

52.27±
28.72

14.90±7.71 Male, BMI
<40

30.7

11

Female,
BMI <40

53.72±
22.3

12.63±5.5 BMI ≥40,

37.48±
19.72

16.46±8.47 Male, BMI

29

14.4

Female,

32.5±16.7

13.2±6.4

Males,
Total

30.92±
21.03

12.09±7.63 Female,
BMI <40

35.8
(36.7)

10.7
(12.8)

Male,
Age <40
years
old

50.2±39

14.2± 4.7

Females,
Total

50.73±
26.68

16.2± .89

30.3

14.8

Male,
Age > 40
years
old

47±10

Age ≤40

48.49±
26.72

15.56±8.01

Female,
Age < 40
years
old

47.3±28

45.28±
27.13

15.31±8.02

BMI ≥40

%EWL

Study #3: Lecumberri et al.

Total

BMI ≥ 40

13.9±2.7

years old

12.9±5.2

Age >40
years old

%TBWL

%EWL

%TBWL

≥40

Female,
BMI ≥ 40

Female,
Age >40
years
old

38±22.5

11.9± 6.9

It is important to note that a portion of data provided by Lecumberri et al. included five overweight
participants with a BMI of 25-29.9, making up 6.1% of the study sample size. These participants do not fit
the inclusion criteria of this literature review; results excluding this data have been calculated by the
writers of this paper and provided in parentheses in Table 10. The %EWL and %TBWL in women with
BMI <40 as well as all participants overall differ minimally between this data excluded and included. Given
the small sample distribution, the minimal differences in %EWL and %TBWL, and the ability to exclude
the necessary data, the writers of this review found it adequate to utilize this study’s results to compare
IGB weight loss outcomes of lower versus higher baseline BMI participants.

Overall effectiveness and safety
The primary goal of each study was to confirm safety and efficacy of the IGB. Each study found
generally similar effectiveness with overall significant weight loss achieved following IGB placements.
%TBWL ranged from 12.8% to 16.46% and %EWL ranged from 29% to 53.72% across subgroups. As
with other trials using gastric balloons, Lopez-Nava et al found that their trial with the IGB produced a
greater %EWL compared to other trials using behavioral and/or pharmacological treatments alone. All
three studies confirmed the EGB was a safe procedure, with minor side effects (nausea, gastric erosion,
etc.) and infrequent events of balloon migration or need for early removal.
Baseline BMI
Each study had a secondary objective of analyzing whether baseline BMI, age, and gender
played a role in weight loss outcomes. All three studies found that participants with lower baseline BMI
had higher %EWL after six months post-treatment. Diab et al reported higher %EWL in lower baseline
BMI participants across age and gender subgroups. Lopez-Nava et al reported %EWL was significantly
higher on non-morbidly obese participants than the morbidly obese (50.7 vs 30.9%). Lecumberri et al
reported that %EWL was higher in lower baseline BMI groups. Across the three studies, no difference
was found in %TBWL between obesity grades.
Gender
Lecumberri et al found no statistical difference between men and women regarding all weight loss
parameters. Similarly, Diab et al found that gender made no difference in %EWL and %TBWL. In
contrast, Lopez-Nava et al had dissimilar results where women had higher %EWL compared to men
(50.73 + 26.68 for women, and 30.92 + 21.03 for men). However, Lopez-Nava et al present a caveat
where these results may be influenced by the lower number of men in their sample size and by the higher
excess weight at baseline in the male participants. This variability in associations between gender and
IGB weight loss outcomes across the studies is likely influenced by the uneven distribution of gender that
occurred in all three study patient populations. Further studies involving IGBs that recruit more male
participants are warranted to learn more about the influence of gender on IGB weight loss.
Age
Lecumberri et al found after adjusting for gender and initial BMI and excluding the outlier patient,
all weight loss endpoints were inversely proportional to age. Alternatively, Diab et al stratified for gender

and age, and found that there was a significant effect of age in females, where women under age 40 had
on average 47.34%EWL while older women had 38%EWL. There was no significant difference between
%EWL based on the age of males in their study. Lopez-Nava et al found no statistically significant
difference in %EWL between age groups.
While the three studies do not agree on age and weight loss correlations after IGB use, there are
hypotheses that attempt to explain why age is considered a hindrance to achieving significant weight loss.
Older patients typically have more comorbidities and decreased mobility compared to younger patients,
making it difficult to lose and keep off excess weight.23 Additionally, increasing age inversely correlates
with energy requirements and lipolysis.24
As previously mentioned, studies on gastric bypass surgery have ascertained that younger
patients with lower baseline BMI see more weight loss success following the procedure than those with
higher baseline BMI.15,16,17,18,19 However, these studies don’t have similar conclusions regarding gender.
Ma et al found that male gender is one of the predictors of higher %EWL with the RYGBP, whereas
Melton et al found that weight loss is suboptimal following a RYGBP with male participants. Questions
have emerged whether the influence of gender, age, and baseline BMI on gastric bypass weight loss
outcomes would reflect similarly in IGB weight loss outcomes; this systematic review discovered that this
is not the case.
Regarding the studies included in this review, Lopez-Nava et al did not make a formal conclusion
in regard to age, gender, or baseline BMI and IGB weight loss outcomes, but overall their findings
suggest no correlation. Conversely, Diab et al concluded that age (in females only) and baseline BMI can
be used as predictors of weight loss outcome in patients treated with IGB. Lecumberri et al had a similar
conclusion to Diab et al, where younger patients and lower baseline BMI patients had better weight loss
outcomes. Finally, further studies are warranted to investigate the relationship of gender and weight loss
outcomes in both IGBs and gastric bypass surgeries.

CONCLUSION
Clinical question: Didobese and morbidly obese patients aged 18-75 with a lower baseline BMI
(BMI 30-39.9 kg/m2) who received an intragastric balloon (IGB), have a higher percentage of total body
weight loss (%TBWL) and percentage of excess weight loss (%EWL) compared to those with a higher
baseline BMI (BMI > 40 kg/m2)?
There are various approaches to weight loss, each with favorable factors that lead to more
successful management of obesity. As with gastric bypass surgery, this review found that a lower
baseline BMI was similarly associated with greater weight loss following IGB placement. All three studies
reviewed found those with lower baseline BMI had a higher %EWL than those with a higher baseline BMI.
However, there was no significant difference in %TBWL. Additionally, the studies all concluded that IGB is
a safe treatment for obese patients and is significantly more effective than behavioral modifications and/or
pharmaceutical management alone. All three studies concluded that gender had little difference in weight
loss outcomes, however there was variability in conclusions on age and baseline BMI. Further studies
with larger, more proportionate sample sizes are required to determine the success of IGBs in relation to
other factors such as age and gender.
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